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Abstract
The flux of platelet agonists into flowing blood is a critical event in thrombosis and hemostasis. However, few
in vitro methods exist for examining and controlling the role of platelet agonists on clot formation and stability
under hemodynamic conditions. In this paper, we describe a membrane-based method for introducing a
solute into flowing blood at a defined flux. The device consisted of a track-etched polycarbonate membrane
reversibly sealed between two microfluidic channels; one channel contained blood flowing at a physiologically
relevant shear rate, and the other channel contained the agonist(s). An analytical model described the solute
flux as a function of the membrane permeability and transmembrane pressure. The model was validated using
luciferase as a model solute for transmembrane pressures of 50–400 Pa. As a proof-of-concept, the weak
platelet agonist ADP was introduced into whole blood flowing at 250 s-1 at three fluxes (1.5, 2.4, and 4.4 ×
10-18 mol µm-2 s-1). Platelet aggregation was monitored by fluorescence microscopy during the experiment
and the morphology of aggregates was determined by post hoc confocal and electron microscopy. At the
lowest flux (1.5 × 10-18 mol µm-2 s-1), we observed little to no aggregation. At the higher fluxes, we observed
monolayer (2.4 × 10-18 mol µm-2 s-1) and multilayer (4.4 × 10-18 mol µm-2 s-1) aggregates of platelets and
found that the platelet density within an aggregate increased with increasing ADP flux. We expect this device
to be a useful tool in unraveling the role of platelet agonists on clot formation and stability.
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The flux of platelet agonists into flowing blood is a critical event in thrombosis and hemostasis. 
However, few in vitro methods exist for examining and controlling the role of platelet agonists on 
clot formation and stability under hemodynamic conditions. In this report, we describe a 
membrane-based method for introducing a solute into flowing blood at a defined flux. The device 10 
consisted of a track-etched polycarbonate membrane reversibly sealed between two microfluidic 
channels; one channel contained blood flowing at a physiologically relevant shear rate, and the 
other channel contained the agonist(s). An analytical model described the solute flux as a function 
of the membrane permeability and transmembrane pressure. The model was validated using 
luciferase as a model solute for transmembrane pressures of 50-400 Pa. As a proof-of-concept, the 15 
weak platelet agonist ADP was introduced into whole blood flowing at 250 sec-1 at three fluxes 
(1.5, 2.4, and 4.4 × 10-18 mol μm-2 sec-1). Platelet aggregation was monitored by fluorescence 
microscopy during the experiment and the morphology of aggregates was determined by post hoc 
confocal and electron microscopy. At the lowest flux (1.5 × 10-18 mol μm-2 sec-1), we observed 
little to no aggregation. At the higher fluxes, we observed monolayer (2.4 × 10-18 mol μm-2 sec-1) 20 
and multilayer (4.4 × 10-18 mol μm-2 sec-1) aggregates of platelets and found that the platelet 
density within an aggregate increased with increasing ADP flux. We expect this device to be a 
useful tool in unraveling the role of platelet agonists on clot formation and stability.  
1. Introduction 
During thrombus formation on the exposed subendothelial 25 
matrix, platelets pause or roll on von Willebrand factor, and 
then arrest and activate on collagen1, 2. Adhered platelets 
become activated through outside-in signaling via 
glycoprotein receptors3. Activated platelets recruit and 
aggregate other platelets by producing soluble agonists and 30 
releasing them into the flowing blood. These agonists include, 
but are not limited to, thrombin4, ADP5, and thromboxane A26. 
The cellular and molecular events of platelet adhesion to 
surface-bound proteins and subsequent platelet activation has 
been extensively studied in animal7-9 and in vitro models10-14. 35 
In vitro models have been critical in defining the shear 
dependent bonding dynamics between platelet receptors and 
their surface bound ligands. Parameters such as on and off 
rates and adhesion efficiency have been measured by 
manipulating the composition and density of surface-bound 40 
ligands15. However, there are no in vitro models for 
manipulating agonist flux into flowing blood. 
 In this report, we describe a membrane based microfluidic 
device for controlling the flux of platelet agonists into flowing 
whole blood. The device consists of two channels separated 45 
by a membrane. One channel contains blood flowing at a 
physiologically relevant mean wall shear rate (250-2000 sec-
1). The second channel, containing the agonist(s), is oriented 
perpendicular to the first channel. At the intersection of the 
two channels, the flux of agonists into flowing blood is 50 
controlled by the concentration of the agonist and the 
transmembrane pressure. Luciferase was used as a model 
solute to examine the roles of wall shear rate, the relative flow 
rates of the two channels, and protein fouling on flux. 
Analytical and numerical models were developed to describe 55 
the fluid flow and mass transport in the device. As a proof-of-
concept, the platelet agonist ADP was introduced at three 
different molar fluxes into flowing whole blood. Post hoc 
electron and confocal microscopy reveal that platelet 
activation and aggregation depend on the magnitude of ADP 60 
flux. This is the first demonstration of user-controlled ADP 
wall flux into flowing blood to trigger platelet deposition. 
2. Experimental 
2.1 Device fabrication and operation 
Figure 1a illustrates the three layers of the device; 1) a top 65 
channel that contains flowing blood, 2) a track-etched 
polycarbonate membrane, and 3) a bottom channel that 
contains the agonist solution and a vacuum chamber. The 
channels were made by (poly)dimethlysiloxane (PDMS) 
molding techniques16. Briefly, a high aspect ratio negative 70 
photoresist (KMPR 1050, MicroChem Corp., Newton, MA) 
was spun and patterned on a silicon substrate at a height of 
100 μm. Microfluidic channels had a cross-sectional area of 
100 μm × 100 μm. In the bottom layer the channel was 
separated by a solid barrier from the vacuum chamber. An 75 
array of 400 μm posts spaced 1 mm apart was used to prevent 
collapse of the vacuum chamber under negative pressure 
(Figure 1c). The bottom channel was a single mold process, 
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PDMS mold off of a photoresist master. The top channel and 
vacuum chamber required a two mold process, with an 
additional PDMS mold off a PDMS master. We found the two 
mold process to provide better pattern transfer of the pillars 
than a single mold process. Inlet and outlet holes were created 5 
in the PDMS using sharpened 23 gauge stainless steel tubing. 
Small diameter tubing (PEEK, ID=150 μm, OD=360 μm, 
Upchurch Scientific, Oak Harbor, WA) was used to make 
external connections to reservoirs of agonist(s) and blood 
solutions and withdrawal syringes. A compression fitting for 10 
connection to the PDMS was made by gluing a larger 
diameter sleeve (PEEK, ID=380 μm, OD=1/16 inch) over the 
end of the small diameter tubing. One foot of tubing was used 
for all four connections, inlet and outlet of both channels. The 
total dead volume in the tubing for each channel was 11 μL. 15 
The flow rate of the top and bottom channels were 
independently controlled with two syringe pumps (PHD 2000, 
Harvard Apparatus, Holliston, MA) driving glass syringes 
(100 μL and 250 μL, Hamilton Co.  Reno, NV). The device 
was assembled by placing a track-etched polycarbonate 20 
membrane (13 mm diameter, B1013-MB, Structure Probe, 
Inc., West Chester, PA) onto a 10 mm platform on the bottom 
PDMS layer. The bottom and top layers were aligned by hand 
using a low magnification stereoscope, brought into contact, 
and vacuum sealed at a pressure of ~40 kPa using a diaphragm 25 
pump (DOA-V163-BN, Gast Manufacturing, Inc., Benton 
Harbor, MI). By design, there was a thin gap between the two 
PDMS layers at the periphery of the membrane. During the 
flow experiments, fluid slowly escaped through this gap into 
the vacuum chamber. Less than 10 μL of fluid was lost 30 
through the gap over one hour. Since the membrane area is 
larger than the PDMS platform there is no cross-
contamination between the two fluid streams. At high wall 
shear rates (1000-2000 sec-1) both the blood and agonist 
reservoirs were at atmospheric pressure and were withdrawn 35 
(negative pressure) via the syringe pumps. In some 
experiments at low all shear rates (250-500 sec-1), the agonist 
solution was infused (positive pressure) and the blood solution 
withdrawn (negative pressure) to a achieve higher 
transmembrane pressure. 40 
2.2 Agonist flux models 
Solute flux through the membrane into a flowing solution is 
determined by the solute properties (size, shape, charge), the 
pore characteristics of the membrane (radius, length, pore 
density), and the operating conditions (concentration gradients 45 
and pressure gradients). Within the blood containing channel, 
the constant flux of agonist leads to the formation of a 
boundary layer which begins at the upstream edge of the 
reaction zone. The thickness of the boundary layer determines 
how many platelets experience threshold concentrations of an 50 
agonist and thus are activated. We developed two models to 
capture each of these events; 1) an analytical model which 
describe the flux of a solute through the membrane and 2) a 
finite element model to capture the fluid dynamics and 
transport within the microfluidic channels. 55 
 
2.2.1 Analytical Model of Agonist Flux 
As a first-order estimate, we treated the membrane as a porous 
medium that uniformly experiences the same pressure drop 
across the entire length and width of the membrane (100 μm × 60 
100 μm) at the intersection between the two channels. The 
transmembrane pressure was obtained by first calculating the 
pressure in each channel and then subtracting the difference 
between the two channels at the intersection point. Owing to 
the small diameter of the PEEK tubing used in the 65 
experiments, we also accounted for the pressure drop through 
the tubing, which in some cases was a significant fraction of 
the overall pressure drop. We analytical expressions to find 
the pressure drop through a rectangular channel per unit 
length and the wall shear rate17: 70 
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where γwall is the mean wall shear rate, A is the channel cross-
sectional area, f is the Fanning friction factor, and Re is the 
Reynolds number based on a characteristic length of A. To 80 
find the transmembrane pressure, eq. 1 was evaluated at the 
half length of both channels (including tubing): 
               2/,22/,1 LLmembrane PPP −=Δ                      (4) 
where ΔPmembrane is the transmembrane pressure, and P1,L/2 and 
P2,L/2 is the pressure in channel 1 and 2, respectively, at the 85 
half length of the channel. The specific discharge of agonist 
from channel 2 into channel 1 was calculated using Darcy’s 
law and the experimentally determined hydraulic permeability 
(see section 2.3.1): 
t
Pkv membranea
Δ
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μ
                             (5) 90 
where va is the agonist velocity through a single pore, k is the 
Darcy’s permeability, and t is the membrane thickness. The 
unhindered agonist flux was calculated by considering both 
diffusive and convective transport through the membrane: 
 aaaa cvcDJ +∇−= ∞                            (6) 95 
where Ja is the agonist flux, D∞ is the agonist diffusion 
coefficient in water, ca is the agonist concentration, and va is 
the mean velocity. In the membranes used in this report the 
agonist was much smaller than the pore (ragonist/rpore<0.01), so 
there were no steric hindrances to transport18. We assume that 100 
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the concentration in the top channel is zero, so that the 
concentration gradient across the membrane is ∇ca=(ca,2-0)/L. 
This assumption overestimates the agonist flux because the 
concentration at the wall in the top channel is nonzero. 
However, in most cases the device is operated at a pore Peclet 5 
number (Pe=vaL/D) greater than 10 and therefore the 
contribution of the diffusive flux to the overall flux is small 
(<10%). 
 
2.2.2 Finite Element Model of Agonist Flux and Distribution 10 
A two-dimensional model of fluid flow and agonist transport 
was developed using commercial finite element software 
(COMSOL Multiphysics, Burlington, MA). The model 
geometry consists of two parallel channels, each with a height 
of 100 μm and a length of 18.5 mm, connected by a 15 
membrane at the half-length. The membrane was modeled as a 
porous medium with a Darcy’s permeability of 3690 nm2 
(Table 1). The fluid in the top layer had the density (1060 kg 
m-3) and viscosity (0.004 Pa s) of whole blood19, but does not 
account for the volume excluded by blood cells. The solution 20 
in the bottom channel had the physical properties of water and 
the diffusivity of ADP was estimated using the Wilke-Chang 
correlation20. 
 The mesh consisted of 303,616 triangular elements. Mesh 
independence was evaluated by comparing the concentration 25 
profiles for grids consisting of 206,436, 303,616 and 375,122 
elements. There was no greater than 2% difference in the 
magnitude of the concentration between the three grid sizes at 
any position within the simulation geometry. The steady state 
mass and momentum conservation equations were solved in 30 
28 minutes using a linear systems solver (UMFPACK) on a 
Linux workstation (dual 2.2 GHz processors, 12 GB RAM). 
2.3 Device characterization 
2.3.1  Membrane hydraulic permeability 
The hydraulic permeability for membranes with a pore 35 
diameter of 0.6 μm and 1 μm and three surface conditions (no 
coating, BSA coated, fibrinogen coated) was determined by 
measuring the flow rate through the membrane under a 
constant pressure head. Protein coatings were achieved by 
incubation of 1 mg/ml BSA or 0.1 mg/ml fibrinogen for two 40 
hours at room temperature followed by thorough rinsing in 
deionized water. Wet membranes were mounted in a filter 
holder (F0101-BA, Structure Probe Inc., West Chester, PA, 
USA). A constant pressure head was provided in a 60 mL 
syringe attached to the top of the filter holder. The flow rate 45 
was determined by measuring the weight of the permeating 
deionized water after 5 minutes on a top loading balance.  
 Water levels of 1.5, 2, and 2.5 inches of water (373, 500, 
627 Pa) were maintained for 5 minutes for 0.6 μm 
membranes. Water levels of 1.5, 2, and 3 inches of water 50 
(373, 500, 750 Pa) were maintained for 5 minutes for 0.6 μm 
membranes.  Each measurement was performed in triplicate 
with a different membrane.  These pressure drops are 
comparable to those across the membrane within the device. 
Using Darcy’s Law (v=k/μ∇P), the permeability was 55 
calculated by a least square fit of the data Q/A versus P/t, 
where Q is the flow rate in m3/s, A is the membrane area in 
m3, P is the pressure drop in Pa, and t is the thickness in m.   
 Previous reports showed that water flux decreases with time 
for track-etched polycarbonate membranes.  In a second set of 60 
experiments, we measured the permeability as function of 
time over 25 minutes at each pressure (250, 500, 750 Pa).   
 
2.3.2  Luciferase molar flux 
The molar flux was adjusted by changing the wall shear rate 65 
in the top channel, the relative flow rate (Q1/Q2), and agonist 
concentration. We used firefly luciferase (61 kDa) as model 
agonist and measured the flux through a polycarbonate 
membrane with an average pore diameter of 1 μm. The flow 
rate in the top channel was set to mean wall shear rates of 70 
250, 500, 1000, and 2000 sec-1 to represent the range of 
venous to arterial shear rates. The relative flow rate between 
the top and bottom channel (Q1/Q2) was varied over a range 
of 0.075-25. In experiments where Q1/Q2>1, fluid was 
withdrawn from both channels. In experiments where 75 
Q1/Q2<1, fluid was withdrawn from the top channel and 
infused into the bottom channel. The fluid in the top channel 
was 1 mg/mL bovine serum albumin (BSA) (Sigma, St. Louis, 
MO) in phosphate buffered saline (PBS). The fluid in the 
bottom channel was 1 nM or 10 nM luciferase and 1 mg/mL 80 
BSA in PBS. The BSA helped minimize adsorption of the 
luciferase to PDMS. Before each experiment the channels and 
membrane were incubated in a 1 mg/mL BSA solution for one 
hour to minimize nonspecific protein adsorption. 
 For each experiment, a total of 100 μL of fluid was 85 
collected from the top channel. Following the experiment, 20 
μL aliquots of fluid from both channels were transferred into 
white 96-well plates in triplicate for each experimental 
condition. Luciferase concentration was determined by flash 
luminescence using a plate reader (2103 Envision, 90 
PerkinElmer, Waltham, MA). An automated dispenser in the 
plate reader injected each well with 100 μL of substrate 
(E4550, Promega Corp., Madison, WI) followed immediately 
by reading the luminescence signal for 10 seconds. Luciferase 
concentration was calculated by integrating the luminescence 95 
signal for nine seconds and comparing the integrated signal to 
a standard curve. A standard curve was generated for each 
plate over the linear range (10 fM to 1 nM) of the 
luminescence assay. The luciferase flux was calculated by 
multiplying the concentration by the flow rate and dividing by 100 
the cross-sectional area (100 μm × 100 μm) where the two 
channels intersect. Each experimental condition was run in 
triplicate on a separate membrane. 
 Membranes used for protein filtration are known to foul 
over time, which can lead to diminished water and solute 105 
flux21, 22. We investigated the role of fouling in this system by 
measuring luciferase flux at different transmembrane 
pressures over 25 minutes. The experimental conditions were 
1 nM luciferase and 1 mg/mL BSA in PBS in the bottom 
channel, 1 mg/mL BSA in PBS in the bottom channel, 110 
Q1/Q2=10 for mean wall shear rates of 2000 sec-1 and 1000 
sec-1, Q1/Q2=0.5 for mean wall shear rates of 500 sec-1 and 
250 sec-1 in the top channel. Fractions were collected every 5 
minutes, diluted to a total volume of 100 μL, and the flux was 
determined following the procedure above. 115 
2.4  Introduction of ADP into flowing whole blood 
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Human whole blood was obtained from healthy volunteers via 
venipuncture and anticoagulated with sodium citrate (9 parts 
blood to 1 part sodium citrate) and corn trypsin inhibitor (50 
μg/ml final concentration) to block Factor XIIa and associated 
intrinsic pathway initiation. Platelets were incubated for five 5 
minutes with an anti-CD41:Alexa 647 antibody 
(MCU467A647, AbD Serotec, Releigh, NC) at a volume ratio 
of 50 parts blood to 1 part antibody. Immediately before 
introduction into the device, the blood was recalcified with 
CaCl2 (100mM in HEPES buffered saline) to a final calcium 10 
concentration of 20 mM. The blood was withdrawn to achieve 
a mean wall shear rate of 250 sec-1 for five minutes. ADP (10 
μM) in HEPES buffered saline (HBS) was perfused at relative 
flow rates of Q1/Q2=0.075, 0.15, 0.3 corresponding to 
transmembrane pressures of 1020, 545, and 308 Pa, 15 
respectively. After five minutes, the blood was replaced with 
HBS and the adhered platelets were washed for five minutes 
at a mean wall shear rate of 100 sec-1. Each experimental 
condition was run in triplicate with blood from a different 
donor. The platelet count for each donor was measured using 20 
a Coulter counter.  
 The device was operated as described in section 2.3.2, 
except that the polycarbonate membrane was incubated in 0.1 
mg/mL human fibrinogen for 2 hours. Adsorbed fibrinogen is 
amenable to activated platelet adhesion through the αIIbβ3 25 
integrin, but does not result in quiescent platelet adhesion at 
the shear rates in this report23. Before introducing blood and 
agonists into the device, the channels were filled with 1 
mg/ml BSA solution in HBS buffer and allowed to flow for 10 
minutes at Q1/Q2=1.  30 
2.5  Post hoc electron and confocal microscopy 
Immediately following a flow experiment, the device was 
dismantled and the membrane was thoroughly washed in HBS 
buffer. The sample was fixed in 2% glutaraldehyde for four 
hours at room temperature and overnight at 4 ºC. The samples 35 
were stored in 0.1 M sodium cacodylate buffer at 4 ºC until 
processing. The day of imaging, the samples were dehydrated 
for 15 minutes in graded ethanol solutions of 50%, 70%, 80%, 
90%, and twice in 100%. For electron microscopy, the 
samples were then critical point dried and sputtered with 40 
Au/Pd. Samples were imaged on a field emission scanning 
electron microscope (Supra 50VP, Carl Zeiss SMT, 
Oberkochen, Germany) at an accelerating voltage of 5 kV. For 
fluorescence microscopy, the samples were coverslipped in 
mounting medium (H-100, Vector Laboratories, Burlingame, 45 
CA) and imaged using a 60x oil immersion objective on a 
spinning disk confocal fluorescence microscope (IX81-DSU, 
Olympus America, Center Valley, PA). 
 To estimate the role of ADP flux on platelet aggregation, 
we calculated the platelet surface and volume density in 50 
aggregates for the different experimental conditions. For each 
membrane, the integrated fluorescence intensity of single 
platelets (n=10) was measured as a baseline value (Fo). The 
integrated fluorescence intensity of each aggregate (Fa) was 
divided by the baseline single platelet value to yield the 55 
number of platelets per aggregate (N=Fa/Fo). We defined the 
platelet surface density as the number of platelets per 
aggregate divided by the aggregate area ( N =N/Aa). We only  
considered platelet aggregates formed in the first 200 μm 
downstream from the reaction zone. The platelet volume 60 
density within an aggregate was measured by dividing the 
surface density by the confocal stack height, which ranged 
from 4-8 μm.  
3  Results 
3.1  Device Characterization 65 
A three layer device consisting of two perpendicular channels 
and a membrane was fabricated for controlling the flux of 
platelet agonists into blood flowing at physiological shear 
rates (Figure 1). The three layers were reversibly sealed 
during operation by vacuum-assisted bonding. The agonist 70 
flux was a function of the membrane properties, the relative 
flow rate of the two channels (Q1/Q2), and the agonist 
concentration in the bottom channel. 
3.1.1  Membrane hydraulic permeability 
The permeability was measured for track-etched 75 
polycarbonate membranes with pore diameter of 0.6 and 1 
μm. Table 1 shows the permeability of membranes with these 
two pore diameters for no surface treatment, adsorbed BSA, 
and adsorbed fibrinogen.   Figure S1 shows the velocity as a 
function of pressure and least squares fit used to determine 80 
permeability.  There is approximately a four-fold smaller 
permeability of the 0.6 μm pore membranes than the 1.0 μm 
pore membrane (k1μm/k0.6μm≈4).   For a porous medium with 
straight cylindrical pores, like track-etch polycarbonate, the 
permeability is proportional to the pore density and the pore 85 
diameter to the fourth power (k α N dpore4)24.  The 
manufacturer reports a pore density of 2 × 107 pores/cm2 for 1 
μm pore diameter membranes and 3 × 107 pores/cm2 for 0.6 
μm pore diameter membranes.  Therefore, the ratio of the 
permeabilities between the two membranes should be 90 
k1μm/k0.6μm=5.1.  However, this estimate does not account for 
dispersity of pore sizes and non-parallel pores, both of which 
could lead to a lower permeability. 
 For a pore diameter of 1 μm there was no significant 
change in the permeability for all three surface conditions. 95 
There was a 43% decrease in permeability for fibrinogen 
treated 0.6 μm pore membranes and no change for BSA-
treated membranes. Based on these results, we chose to use 
the 1 μm pore membranes for device characterization and 
blood experiments since there was no change in permeability 100 
between BSA and fibrinogen surface treatments. 
 Previous reports have shown a decrease in water flux with 
time for track-etched polycarbonate membranes24, 25.  Figure 
S2 shows the decline in water flow rate for membranes with a 
1 μm average pore diameter as function fo time.  For constant 105 
pressure heads of 250, 500, and 750 Pa there was a 11.0%, 
10.5%, and 4.4% decline in water flux over 25 minutes, 
respectively.  The flux decline may be due to particulates in 
the water and bubbles forming within the pores.  Mueller and 
Davis reported a 41-60% water flux decline in track-etched 110 
polycarbonate membranesover the same time, albeit for 
smaller pores (0.2 mm) and much larger pressures (69,000-
138,000 Pa)25. 
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3.1.2  Luciferase molar flux 
The agonist flux was manipulated by varying three 
parameters; relative flow rate, wall shear rate, and agonist 
concentration. Varying the relative flow rate and wall shear 
rate were both methods for changing the pressure drop across 5 
the membrane. Varying the agonist concentration changed the 
concentration gradient between the two channels. Figure 2a 
shows the luciferase flux as function of the relative flow rate 
(Q1/Q2) for a mean wall shear rate of 1000 sec-1 and 2000 
sec-1 in the top channel. The luciferase flux was modulated by 10 
almost one order of magnitude at 2000 sec-1 by changing the 
relative flow rate from 1 to 25. Decreasing the flow rate in the 
bottom channel (agonist) to less than 10% of the flow rate in 
the top channel results in negligible changes in agonist flux. 
The analytical model qualitatively describes the trend 15 
measured in the data, but tends to underestimate the agonist 
flux by 10-20% at these wall shear rates. 
 Figure 2b shows the decline in luciferase flux as a function 
of time for four wall shear rates.  The mean wall shear rates 
were 2000, 1000, 500, and 250 sec-1, which corresponded to 20 
transmembrane pressures of 550, 275, 120, and 60 Pa.  Over a 
25 minute experiment there was an average luciferase flux 
decline of 50% (550 Pa), 37% (275 Pa), 40% (120 Pa), and 
49% (60 Pa).  Mueller and Davis reported a 98% decline in 
BSA flux (feed concentration 1 mg/mL) over the same time in 25 
a 0.2 mm pore polycarbonate membrane for a transmembrane 
pressure of 138,000 Pa25.  Similar to our results, they did not 
find the transmembrane pressure to affect the rate of fouling.   
 Figure 2c compares the experimental flux to the theoretical 
flux (k=3690 nm2) from the analytical model developed in 30 
Section 2.2.1.  The flux depends linearly on transmembrane as 
predicted by eqn. 6 for all times, however the model does not 
describe the change in permeability as a function of time.  
Since the percent decline was similar for all pressures, there 
was significantly larger changes in the magnitude of the flux 35 
at higher transmembrane pressures.  This fact was most 
evident at a transmembrane pressure of 550 Pa, the where 
model underestimates flux at early times and overestimated 
flux at late times. 
3.2  Platelet aggregation as a function of ADP flux 40 
ADP (10 μM) was introduced at relative flow rates of 0.075, 
0.15, and 0.3 into whole blood flowing at a mean wall shear 
rate of 250 sec-1 over a fibrinogen coated membrane. These 
relative flow rates correspond to ADP molar fluxes of 4.4, 2.4, 
1.5 × 10-18 mol μm-2 sec-1 (eq. 6), respectively.  Identical 45 
experimental conditions using an ADP feed concentration fo 1 
μM resulted in negligible platelet adhesion.   
 The adhesion and aggregation of platelets was monitored in 
real-time using fluorescence microscopy (Figure 3).  Imaging 
through several layers of material (glass, PDMS, and 50 
polycarbonate) diminished the resolution of images, but 
nevertheless allowed for real-time monitoring of platelets 
adehsion.  Individual platelets were resolved at early times 
(Figure 3a).  A possible improvement of the device is to 
replace the bottom PDMS layers with channels etched in 55 
glass, thereby removing a layer and improving resolution.   
 Following the experiment, the membrane was removed 
from the device and prepared for either electron or confocal 
microscopy. Figure 4 demonstrates that the area and height of 
platelet aggregates depends on ADP flux. There were no 60 
platelet aggregates formed at the lowest ADP flux. Aggregates 
of 20-250 platelets were observed at an ADP flux of 2.4 × 10-
18 mol μm-2 sec-1. These aggregates tended to be monolayers 
and had a platelet surface density of 0.21±0.05 platelets μm-2 
(n=24) and an average volume density of 5.22 × 107 platelets 65 
μL-1. Aggregates of 75-1000 platelets were observed at an 
ADP flux of 4.4 × 10-18 mol μm-2 sec-1. These aggregates 
often contained multiple layers of platelets and had a platelet 
surface density of 0.31±0.04 platelets μm-2 (n=11) and an 
average volume density of 3.45 × 107 platelets μL-1. The 70 
volume density of platelets within aggregates was 174 fold 
and 115 fold greater than the average platelet plasma density 
for an ADP flux of 4.4 × 10-18 mol μm-2 sec-1  and 2.4 × 10-18 
mol μm-2 sec-1, respectively. 
 Observations from electron microscopy of aggregates show 75 
that the morphology of platelets was qualitatively different at 
a higher ADP flux (Figure 5). At the lowest ADP flux 
(Q1/Q2=0.3), platelets adhered only to the 100 μm × 100 μm 
reaction zone where the two channels intersected. In addition, 
most of these platelets maintained their quiescent discoid 80 
shape and did not form aggregates (Figure 5a). At the middle 
ADP flux (Q1/Q2=0.15), platelet adhesion was not limited to 
the reaction zone and aggregates were observed up to one 
millimeter downstream from the reaction zone. The presence 
of filopodia protruding from cell bodies and platelet-platelet 85 
tethers clearly indicates activated platelets (Figure 5b). 
 The size and height of platelet aggregates increased with 
increasing ADP flux as expected from consideration of the 
ADP distribution in the top channel. A boundary layer of ADP 
begins to form at the upstream edge of the membrane and 90 
grows over the length of the membrane (Figure 6a). 
Downstream from the membrane, the boundary layer begins to 
dissipate by diffusion into the bulk solution. The thickness of 
the boundary layer depends on the ADP flux through the 
membrane. Figure 6b illustrates this dependence for the three 95 
operating conditions considered in the ADP experiments. As 
the flux increases, the thickness of the boundary layer 
increases, and therefore more flowing platelets are activated 
and aggregate. At the middle ADP flux (2.4 × 10-18 mol μm-2 
sec-1) most of the aggregates were monolayers of platelets, 100 
whereas at the high ADP flux (4.4 × 10-18 mol μm-2 sec-1) 
there were several multilayer aggregates. 
4  Discussion 
Platelet adhesion to surface-bound protein on the 
subendothelium is the initial condition of blood coagulation.  105 
Following adhesion, the platelets become activated and in turn 
generate thrombin and thromboxane A2 on their extracellular 
membranes and release ADP from intracellular stores to 
promote further platelet activation and aggregation. The 
release of these platelet agonists into the blood flowing over 110 
the adhered platelets is the boundary condition that leads to 
platelet aggregation. The flux of these three agonists into 
flowing blood serves an important role in thrombosis and 
hemostasis. However, the combined function of such soluble 
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agonists during clot formation under flow is unknown, since 
no method allows controlled fluxes of agonists into flowing 
blood. The relationship between solute flux and stable clot 
formation is a complex reaction-transport problem with 
coupled particle deposition. One example of altered solute 5 
flux is hemophilia, where deficiencies in clotting factors 
attenuates thrombin generation26, which leads to unstable 
clots27. It is less clear whether these clots are unstable because 
of diminished fibrin formation or diminished platelet 
activation, or both. The device described in this report 10 
provides a method for manipulating solute flux that could be 
useful for studying hemophilia and other bleeding disorders. 
 The size and growth of a thrombus is limited by the 
interplay between activated platelets and intact endothelial 
cells.  Endothelial cells secrete soluble molecules (nitric 15 
oxide, prostacyclin, ecto-necleotidases) that control platelet 
reactivity in a process known as thromboregulation28.  The 
device presented in this report could be extended to study 
thromboregulation with additional bottom channels for 
introduction of these platelet antagonists.  20 
 Incorporation of membranes into microfluidic devices is 
becoming increasingly common for on-chip filtration and 
separations, as well as a component for sensors, reactors, and 
cell culture29. In this report we incorporated commercially 
available membranes as fluidic resistor into a microfluidic 25 
device by modifying a technique first reported by Ismagilov 
and colleagues30. This technique has been employed for 
screening biochemical interaction30, generating chemical 
gradients31, and monitoring communication between different 
cell types32. A notable modification we have made was the use 30 
of vacuum assisted bonding33. This reversible bonding 
technique allowed for post hoc morphological analysis of 
platelet aggregates by electron and spinning disk confocal 
microscopy. 
 Track-etched polycarbonate membranes demonstrate both 35 
internal and external fouling under different operating 
conditions24, 25, 34.  Internal fouling describes the adsorption 
and deposition of molecules and particles onto the surface of 
the pore, and consequently reducing the pore size.  External 
fouling describes the accumulation of larger particles and 40 
cells that cannot enter pores.  We have chosen a membrane 
whose pores are much larger than any of the solutes we are 
interested in introducing into blood, but also small enough to 
exclude blood cells. However, we still observed fouling of the 
pores that lead to significant flux decline over 25 minutes. 45 
This flux decline was most likely the result of internal fouling 
based on moderate transmembrane pressures and short length 
of the experiments25.  Other choices of membranes include 
cellulose acetate, polyvinylidene fluoride, or polysulfone.  
However, these other membranes have a minimum thickness 50 
on the order of 100’s microns, whereas the polycarbonate 
membranes are 5-15 μm thick.  The membrane thickness is an 
important parameter in the multilayer device described in the 
manuscript.  We attempted to use a cellulose acetate 
membrane (thickness=110 μm) and found that the loss of fluid 55 
into the vacuum chamber was prohibitive.   
 Solute transport was accurately predicted with an analytical 
model when convection was the dominant transport 
mechanism within the pores (Pe>10). Although the model did 
not account for protein fouling, it was a good first-order 60 
etstimate of flux that only required two parameters, the 
membrane permeability and transmembrane pressure.  The 
device was operated in two configurations that depended on 
the wall shear rate in the top channel. At higher wall shear 
rates (1000-2000 sec-1), there was a large enough 65 
transmembrane pressure generated by the top channel to 
achieve predominantly convective transport in the pores. At 
these high shear rates, fluid was withdrawn (negative 
pressure) from both channels. At lower wall shear rates (250-
500 sec-1), the transmembrane pressure generated by the top 70 
channel was insufficient to ensure convective transport. 
Therefore, at these low shear rates, the bottom channel was 
infused (positive pressure) to compensate for small pressure 
drop in the top channel. In some applications, such as gradient 
generation, diffusion-mediated transport may be preferable. 75 
This mode of operation is achievable by withdrawing fluid 
from both channels at the same flow rate, provided the 
channels have the same length and cross-sectional area.  
 As a demonstration of the device, we examined the 
dependence of platelet aggregation on ADP flux. We observed 80 
that platelet activation, aggregation size, and aggregation 
height depended on the magnitude of ADP flux. At the lowest 
ADP flux considered, there was sparse adhesion of platelets 
and little evidence of aggregation and platelet-platelet 
tethering. At the higher fluxes, we observed aggregates of 85 
hundreds of activated platelets. The size and height of 
aggregates increased with increasing ADP flux. These 
observations agree with previous reports that platelet adhesion 
efficiency to fibrinogen coated surfaces increases with ADP 
induced activation23. In addition, computational studies 90 
predict that a thicker agonist boundary layer yields greater 
platelet aggregation35-37. In these computational studies, 
boundary layer thickness and thus platelet aggregation was 
modulated by changing the wall shear rate. However, 
increasing the agonist flux has a similar effect to decreasing 95 
the wall shear rate. 
5  Conclusions 
We have fabricated and characterized a membrane-based 
microfluidic device for controlling the flux of platelet agonists 
into flowing blood. The molar flux of luciferase was 100 
accurately predicted at high pore Peclet numbers using an 
analytical model. The introduction of ADP (1.5-4.4 × 10-18 
mol μm-2 sec-1) into flowing whole blood resulted in flux 
dependent platelet aggregation and activation. We expect this 
device will be a useful tool in unraveling the role of platelet 105 
agonists on clot formation and stability. 
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Table 1  The Darcy’s permeability was measured for track-etched 
polycarbonate membranes with an average pore diameter of 0.6 μm and 1 
μm for three surface treatments; no treatments, incubation in 1 mg/mL 
bovine serum albumin (BSA), incubation in 0.1 mg/mL fibrinogen.  The 5 
permeability values were calculated by a least squares fit of water 
velocity as a function of pressure drop across the membrane for three 
transmembrane pressures (Figure S1).  The goodness-of-fit was measured 
by the R2 statistic.   
Treatment Pore Diameter 
(μm) 
Darcy’s Permeabilitya 
(nm2) 
R2 
No coating 1 3720 0.97 
BSA 1 3530 0.90 
Fibrinogen 1 3690 0.90 
No coating 0.6 905 0.97 
BSA 0.6 965 0.97 
Fibrinogen 0.6 519 0.90 
a See Figure S1 for velocity versus pressure data. 10 
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Fig. 1 (a) The device consisted of two perpendicular channels in PDMS separated by a polycarbonate membrane. The two PDMS layers are reversibly 
sealed using vacuum assisted bonding. (b) At the intersection of the two channels, the flux of the agonist molecules was controlled by the pore size and 
transmembrane pressure. The transmembrane pressure was manipulated by varying the relative flow rate (Q1/Q2) between the top and bottom channels. 5 
(c) Electron micrograph of the bottom channel and posts in the vacuum chamber, which provided mechanical support during operation. 
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Fig. 2 (a) For the mean wall shear rates of 1000 sec-1 and 2000 sec-1 in the 
top channel, the flux was manipulated by changing the relative flow rate 
(Q1/Q2). The flow rate in the top channel, Q1, was held constant to 5 
achieve a desired wall shear rate, and Q2 was changed to vary the 
transmembrane pressure. The solid lines represent the luciferase flux 
predicted by eqn. 6. (b)  The luciferase flux decreased with time due to 
fouling of the pores for wall shear rates of 250, 500, 1000, and 2000 sec-1.  
(c)  The flux data in (b) plotted as function of transmembrane pressure,. 10 
The line represents the predicted for a Darcy’s permeability of 3690 nm2. 
Each data point represents the mean and the error bars represent the 
standard deviation (n=3). 
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Fig. 3 Real-time fluorescence microscopy of platelet adhesion and 
aggregation for a mean wall shear rate of 250 sec-1, 10 μM ADP in the 
bottom channel, and Q1/Q2=0.075 at (a) 1, (b) 3, and (c) 5 minutes.  5 
Scale bar=50 μm. 
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Fig. 4 Spinning disk confocal images (a-c) and volume reconstruction (d-f) of platelet aggregates formed by introducing ADP into flowing whole blood at 
a defined flux. (a,d) At the highest flux (4.4 × 10-18 mol μm-2 sec-1), there were 2-3 layers of platelets and aggregates with 7a surface density of 0.31±0.04 
platelets μm-2. (b,e) At the middle flux (2.4 × 10-18 mol μm-2 sec-1) there were monolayers of platelets and aggregates with a surface density of 0.21±0.05 5 
platelets μm-2. (c,f) At the lowest flux (1.5 × 1010-18 mol μm-2 sec-1), no aggregates were observed, but there was platelet adhesion within the reaction 
zone. Scale bar=10 μm (a-c) and grid spacing=5 μm (d-f). 
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Fig. 5 Electron microscopy of adhered and aggregated platelets at the 
reaction zone. (a) At the lowest ADP flux (Q1/Q2=0.3), platelets adhered 
in singlets or small aggregates (2-5 cells). (b) At the higher ADP flux 5 
(Q1/Q2=0.15), platelets had multiple filopodia protruding from their cell 
bodies and formed aggregates.  Scale bar=5 μm. 
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Fig. 6 :  (a) Simulation of the boundary layer formed when ADP (Q1/Q2=0.15) was introduced into whole blood flowing at a wall shear rate of 250 sec-1. 
(b) The simulation predicts that the thickness of the boundary layer increases with increasing ADP flux. The ADP concentration was plotted as a function 
of vertical distance, represented by the white line in (a), and relative flow rate at the edge of the reaction zone. 5 
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Fig S1 The hydraulic permeability of track-etched polycarbonate membranes was determined by a least squares fit of the velocity versus pressure drop 
(eqn. 5).  Surface treatments of BSA and fibrinogen did not affect the permeability of membranes with a pore diameter of 1 μm.  Fibrinogen treatment, but 5 
not BSA treatment, resulted in a decrease in permeability of membranes with a pore diameter of 0.6 μm. 
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Fig. S2 The water flux through a track-etched polycarbonate membrane with a pore diameter of 1 mm.  For constant pressure heads of 250, 500, and 750 
Pa there was a 11.0%, 10.5%, and 4.4% decline in water flux over 25 minutes.
 5 
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This report describes a membrane-based method for controlling the flux of soluble agonists into flowing blood. The device allows 5 
for real-time measurements of cellular adhesion and aggregation, as well as post hoc microscopy for examining aggregate 
morphology.     
 
